Silent AF in AMI severely impairs long term prognosis, including rehospitalization for heart failure and death. Our large prospective study suggests that silent AF screening should be improved after AMI in order to identify patients at high risk for long term events.
Background:
The benefit of anticoagulants (AC) to prevent thrombotic complications during percutaneous coronary intervention (PCI) is well established. In acute coronary syndrome (ACS) patients previously treated with enoxaparin, an additional bolus of AC is not recommended if the last injection was realized within 8 h. In this setting, many interventional cardiologists use unfractionated heparin (UFH) at the time of sheath insertion.
Objectives:
The aim of our study was to describe local current practices for AC use during PCI in patients already treated with enoxaparin and admitted for ACS and to assess the biological impact of UFH addition at the beginning of the procedure.
Methods:
A standardized survey was sent to the interventional cardiologists of the southwest of France to investigate their practice in terms of periprocedural AC use. In 2 centers, ACS patients previously treated with subcutaneous injection of enoxaparin within 8 h and who received intravenous UFH at the time of sheath insertion were prospectively included and their plasma anti-Xa activity was assessed at the sheath insertion and 30 min after UFH bolus. In-hospital bleeding and ischemic events were collected. The adequate therapeutic window was defined by anti Xa activity (range 0.5 to 0.9 IU/mL). Results: Among the 41 interventional cardiologists who replied, a large majority (75,6%) considered the addition of UFH in patients who received enoxaparin within 8 h as a valid option. 47 ACS patients were enrolled. The dose of the bolus of UFH was highly variable from 20 to 90 UI / kg. Anti-Xa activities were above 0.9 IU/mL in 14,9% of patients at the sheath insertion and in 72,3% of patients 30 min after UFH injection. 2 bleeding complications occurred, both in over-coagulated patients. No ischemic events were reported.
Conclusion:
The use of UFH in patients who already received enoxaparin may result in over-anticoagulation and lead to bleeding complications.
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Background: Prevalence and correlates of prolonged dual antiplatelet therapy (DAPT) in stable coronary artery disease (CAD) are unknown. Our aims were to assess the proportion of stable CAD patients under long-term DAPT and the correlates of its prescription, and to analyze its impact on prognosis.
Methods: Between 2010 and 2011, 3691 patients with stable CAD for at least 1 year (median 4 years) were divided in 2 groups according to their antiplatelet therapy regimen at inclusion: patients under DAPT were compared to those under single antiplatelet therapy (SAPT).
Results:
Altogether, 868 (24%) patients received DAPT. Factors associated with long-term DAPT were a time interval since the last coronary event <3 years, more multivessel and peripheral disease, prior drug eluting stent implantation and markers for a lower bleeding risk (younger patients, higher body mass index). After propensity score matching, the rate of the composite endpoint (death, myocardial infarction, stroke) at 2 years was similar between patients with or without DAPT: 5.5% versus 5.7% (p=0.9). The rate of bleeding was also similar between groups: 1% versus 0.7%, respectively (p=0.6).
Conclusions:
Our study shows that a high proportion of stable CAD patients is under DAPT in modern practice. Several correlates of DAPT were identified. Of note and even so no increase in bleeding was observed, our results do not support the prescription of prolonged DAPT.
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